Insulet Corp
NASDAQ:PODD

Watchlist Manager
Insulet Corp Logo
Insulet Corp
NASDAQ:PODD
Watchlist
Price: 283.51 USD 0.21% Market Closed
Market Cap: 19.9B USD

Insulet Corp
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Insulet Corp
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Insulet Corp
NASDAQ:PODD
Cash from Operating Activities
$533.7m
CAGR 3-Years
132%
CAGR 5-Years
36%
CAGR 10-Years
48%
Becton Dickinson and Co
NYSE:BDX
Cash from Operating Activities
$3.4B
CAGR 3-Years
9%
CAGR 5-Years
-1%
CAGR 10-Years
7%
Boston Scientific Corp
NYSE:BSX
Cash from Operating Activities
$4.6B
CAGR 3-Years
57%
CAGR 5-Years
25%
CAGR 10-Years
21%
Stryker Corp
NYSE:SYK
Cash from Operating Activities
$4.8B
CAGR 3-Years
23%
CAGR 5-Years
12%
CAGR 10-Years
18%
Abbott Laboratories
NYSE:ABT
Cash from Operating Activities
$9.1B
CAGR 3-Years
-4%
CAGR 5-Years
7%
CAGR 10-Years
10%
Intuitive Surgical Inc
NASDAQ:ISRG
Cash from Operating Activities
$3B
CAGR 3-Years
22%
CAGR 5-Years
16%
CAGR 10-Years
16%
No Stocks Found

Insulet Corp
Glance View

Insulet Corporation has carved out a significant niche in the medical device industry, distinguishing itself through its innovative approach to diabetes management. The company is best known for its Omnipod Insulin Management System, a discreet, tubeless insulin pump that provides a solution for individuals with diabetes seeking an alternative to traditional insulin delivery methods. Unlike conventional pumps that require cumbersome tubes and significant patient involvement, the Omnipod system offers ease and convenience, allowing users more freedom and flexibility in their daily lives. The system operates via a small wearable pod that delivers insulin over several days, which users control remotely, removing much of the hassle associated with managing diabetes. Insulet generates revenue by selling these pods and the associated Personal Diabetes Manager (PDM) devices, which together comprise the entire system. Customers typically purchase pods on a recurring basis, similar to a subscription model, which creates a steady stream of revenue for the company. The business model emphasizes continuous growth by expanding its user base and improving its technology to remain at the forefront of patient-centric diabetes care. Insulet's strategic focus on the needs of its users and commitment to refining their health technology has enabled it to build a sustainable business that addresses a critical healthcare challenge while also delivering consistent financial performance.

PODD Intrinsic Value
194.62 USD
Overvaluation 31%
Intrinsic Value
Price

See Also

What is Insulet Corp's Cash from Operating Activities?
Cash from Operating Activities
533.7m USD

Based on the financial report for Sep 30, 2025, Insulet Corp's Cash from Operating Activities amounts to 533.7m USD.

What is Insulet Corp's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
48%

Over the last year, the Cash from Operating Activities growth was 63%. The average annual Cash from Operating Activities growth rates for Insulet Corp have been 132% over the past three years , 36% over the past five years , and 48% over the past ten years .

Back to Top